CDP6038 (olokizumab)

BIOLOGICAL2 trials

Sponsors

UCB BIOSCIENCES, Inc.

Conditions

Rheumatoid Arthritis

Phase 2

Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056

TerminatedNCT01296711

UCB BIOSCIENCES, Inc.Rheumatoid Arthritis

Start: 2011-03-07End: 2013-08-05Updated: 2022-04-14

The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis

TerminatedNCT01533714

UCB BIOSCIENCES, Inc.Rheumatoid Arthritis

Start: 2012-01-26End: 2013-11-29Updated: 2022-05-20

Related Papers

Efficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb study.

2014-03-18106 citations